One of the world's biggest cancer conferences is happening right now. Here are 5 breakthroughs they're talking about: 1. The world's leading cause of cancer death (lung cancer) now has a therapy that cut the risk of death by 58%, moving median survival from 12.7 to 21.1 months (small cell lung cancer). 2. A new personalized therapy for Melanoma can train the immune system in cancer patients and alongside a common cancer med, it cut the risk of recurrence or death by 42%. 3. A therapy has been FDA approved to allow certain people with a subset of rectal cancers to skip chemo, radiation, and surgery. Around half of patients so far were cancer free over a year later. Colorectal cancer is the deadliest cancer in Americans under 50. 4. Chinese researchers presented data on a new therapy for breast cancer where it more than doubled the time before the cancer began to worsen. 5. Another huge therapy saw median survival increase by almost 50% in a specific mutated type of lung cancer, while also lowering decreasing severe side effects. (NSCLC type) See sources below.

This breakthrough cancer conference news is changing everything

5 major things just happened in medicine this week: 1. A breast cancer drug more than doubled the time before the cancer started growing again in a Phase 3 trial (16.4 mo vs 6.8 mo). 2. The world’s deadliest cancer (lung) was treated with a new therapy that cut the risk of death by 58% in a Phase 3 trial. 3. Chronic Hepatitis B now has a functional cure for certain patients after accelerated FDA-approval. 4. Retatrutide put up huge numbers at a sleep medicine conference showing it cut the amount of sleep apnea events in half on the highest doses, in a Phase 3 trial. 5. The leading cause of cancer death under 50 (colorectal, here specifically rectal) now has an FDA approved therapy allowing certain patients to skip chemo, radiation, and surgery.

10/24/26: The world's deadliest cancer has just seen a therapy succeed in a pivotal Phase 3 clinical trial. Tarlatamab + durvalumab cut the risk of death by 58% vs durvalumab alone for small-cell lung cancer (extensive-stage). Currently, just 3.6% of these patients are alive after 5 years.

BREAKING: New breast cancer drug more than doubled the time before the cancer started growing again in a pivotal Phase 3 clinical trial. This type of tumor affects up to roughly half of all breast cancers. #cancer #breastcancer #breakingnews

Medical Myths Evidence-Based True or False